Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
629 participants
Study Classification
OBSERVATIONAL
Study Start Date
2015-01-01
Study Completion Date
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Investigators' aim is to assess whether the administration of amiodarone during resuscitation could cause a reduction of the values of the amplitude spectral area (AMSA).
Amiodarone is recommended for the treatment of cardiac arrest due to ventricular tachycardia/ventricular fibrillation (VT/VF) ( with a low level of recommendation cause of conflicting results. AMSA is a parameter expressing the amplitude of VF and it has been shown to predict defibrillation success and the return of spontaneous circulation (ROSC). No data are available so far about the impact of amiodarone administration on AMSA values.
Amiodarone is recommended for the treatment of cardiac arrest due to ventricular tachycardia/ventricular fibrillation (VT/VF) ( with a low level of recommendation cause of conflicting results. AMSA is a parameter expressing the amplitude of VF and it has been shown to predict defibrillation success and the return of spontaneous circulation (ROSC). No data are available so far about the impact of amiodarone administration on AMSA values.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Real Time Amplitude Spectrum Area to Guide Defibrillation
NCT03237910
Out-Of-Hospital Cardiac Arrest
Ventricular Fibrillation
TERMINATED
NA
Prophylactic Amiodarone for Shockable Cardiac Arrest
NCT04845607
Cardiac Arrest
Ventricular Arrythmia
UNKNOWN
PHASE3
Prophylactic Anti-aRrhythmic Therapy With Amiodarone in Critically Ill Patients Admitted for an Out-of-hospital Cardiac Arrest With Initial Shockable Rhythm
NCT06835491
Ventricular Arrhythmias and Cardiac Arrest
RECRUITING
PHASE3
PROSPECTIVE ANALYSIS BETWEEN AMIODARONE Versus LIDOCAINE IN SVT
NCT03299517
Arrhythmias Ventricular
UNKNOWN
PHASE4
Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia
NCT01401647
Cardiac Arrest
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary study endpoint of the present study is to determine whether patients who received amiodarone during advanced resuscitation had lower values of AMSA as compared to those who did not receive amiodarone.
Secondary endpoints
The secondary endpoints of this study are:
1. To assess, after correction for confounders, the rate of successful defibrillation, the rate of ROSC and the rate of short-term survival (survived event or survival to hospital discharge according to the available data) both in the amiodarone and non-amiodarone group.
2. To assess the role of AMSA for shock success and ROSC prediction in amiodarone group and in non-amiodarone group.
Type of study. This is a multicentre study based on a retrospective analysis of prospectically collected data.
Study population All the out-of-hospital cardiac arrests (OHCA) which occurred from January 1st, 2015 to December 31st, 2020 will be considered for the present study. In the analysis the investigators will include only those patients who received at least one shock for ventricular fibrillation during advanced resuscitation regardless whether or not the presenting rhythm was shockable or non-shockable.
The study cohort will involve cases retrieved from the Lombardia CARe registry (Lombardia Cardiac Arrest Registry NCT03197142), from the registry of Oslo and Vestfold
Data Collection Data from different databases will be integrated and combined in a single ad hoc database for statistical analysis.
For every shock, both pre-shock carbon dioxide at the end ot the tidal volume (ETCO2) and pre-shock AMSA will be calculated. The median ETCO2 value in the minute before the shock (METCO2) will be computed automatically either from a capnogram, when available, applying the algorithm described by Aramendi et al, or from the defibrillator with a ETCO2 monitoring feature. AMSA will be computed using a 2-second-pre-shock ECG interval, free of chest compression artifacts, leaving a 1-second guard before the shock. The electrocardiogram (ECG) will be bandpass filtered (0.5-30Hz) and the fast Fourier transform computed to obtain AMSA in the 2-48 Hz bandwidth.
For each patient all the pre-hospital variables will be included according to the 2014 Utstein recommendations and the number of shocks will be computed. The mean value of both ETCO2 and of AMSA will be calculated.
Statistical analysis Categorical variables will be compared with the Chi-square test and presented as number and percentage. Continuous variables will be compared with the t-test and presented as mean ± standard deviation, or compared with the Mann-Whitney test and presented as median and interquartile range (IQR) according to normal distribution tested with the D'Agostino-Pearson test. A multivariable regression model will be fitted both for shock success and for ROSC (including all non-correlated potential predictors) and to test the effect of amiodarone on AMSA values after correction for confounders.
The values of AMSA in the amiodarone and in the non-amiodarone group will then be compared in two groups of shocks randomly matched and identified via propensity score matching, so that they are homogeneous for time to shock, pre-shock ETCO2, outcome of defibrillation and the age of the patients.
Secondary endpoints
The secondary endpoints of this study are:
1. To assess, after correction for confounders, the rate of successful defibrillation, the rate of ROSC and the rate of short-term survival (survived event or survival to hospital discharge according to the available data) both in the amiodarone and non-amiodarone group.
2. To assess the role of AMSA for shock success and ROSC prediction in amiodarone group and in non-amiodarone group.
Type of study. This is a multicentre study based on a retrospective analysis of prospectically collected data.
Study population All the out-of-hospital cardiac arrests (OHCA) which occurred from January 1st, 2015 to December 31st, 2020 will be considered for the present study. In the analysis the investigators will include only those patients who received at least one shock for ventricular fibrillation during advanced resuscitation regardless whether or not the presenting rhythm was shockable or non-shockable.
The study cohort will involve cases retrieved from the Lombardia CARe registry (Lombardia Cardiac Arrest Registry NCT03197142), from the registry of Oslo and Vestfold
Data Collection Data from different databases will be integrated and combined in a single ad hoc database for statistical analysis.
For every shock, both pre-shock carbon dioxide at the end ot the tidal volume (ETCO2) and pre-shock AMSA will be calculated. The median ETCO2 value in the minute before the shock (METCO2) will be computed automatically either from a capnogram, when available, applying the algorithm described by Aramendi et al, or from the defibrillator with a ETCO2 monitoring feature. AMSA will be computed using a 2-second-pre-shock ECG interval, free of chest compression artifacts, leaving a 1-second guard before the shock. The electrocardiogram (ECG) will be bandpass filtered (0.5-30Hz) and the fast Fourier transform computed to obtain AMSA in the 2-48 Hz bandwidth.
For each patient all the pre-hospital variables will be included according to the 2014 Utstein recommendations and the number of shocks will be computed. The mean value of both ETCO2 and of AMSA will be calculated.
Statistical analysis Categorical variables will be compared with the Chi-square test and presented as number and percentage. Continuous variables will be compared with the t-test and presented as mean ± standard deviation, or compared with the Mann-Whitney test and presented as median and interquartile range (IQR) according to normal distribution tested with the D'Agostino-Pearson test. A multivariable regression model will be fitted both for shock success and for ROSC (including all non-correlated potential predictors) and to test the effect of amiodarone on AMSA values after correction for confounders.
The values of AMSA in the amiodarone and in the non-amiodarone group will then be compared in two groups of shocks randomly matched and identified via propensity score matching, so that they are homogeneous for time to shock, pre-shock ETCO2, outcome of defibrillation and the age of the patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Out-Of-Hospital Cardiac Arrest
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_CONTROL
Study Time Perspective
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Amiodarone group
Patients who did receive amiodarone during the attempt of resuscitation
Amiodarone Injection
Intervention Type
DRUG
NO Amiodarone
Patients who did receive amiodarone during the attempt of resuscitation
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amiodarone Injection
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
clinical:
* patients with out-of-hospital cardiac arrest
* shockable presenting rhythm
* resuscitation attempted
* advanced resuscitation attempted
technical: - VF cardiac arrest (and not VT)
* patients with out-of-hospital cardiac arrest
* shockable presenting rhythm
* resuscitation attempted
* advanced resuscitation attempted
technical: - VF cardiac arrest (and not VT)
Exclusion Criteria
clinical:
* non-shockable presenting rhythm
* resuscitation not attempted
technical:
\- AMSA not evaluable
* non-shockable presenting rhythm
* resuscitation not attempted
technical:
\- AMSA not evaluable
Minimum Eligible Age
1 Year
Maximum Eligible Age
100 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of the Basque Country (UPV/EHU)
OTHER
Sponsor Role
collaborator
Oslo University Hospital
OTHER
Sponsor Role
collaborator
The Hospital of Vestfold
OTHER
Sponsor Role
collaborator
Fondazione IRCCS Policlinico San Matteo di Pavia
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Simone Savastano
principal investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fondazione IRCCS Policlinico San Matteo
Pavia, , Italy
Site Status
Oslo University Hospital
Oslo, , Norway
Site Status
Vestfold Hospital trust
Tønsberg, , Norway
Site Status
BioRes Research Group
Bilbao, , Spain
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Italy
Norway
Spain
References
Explore related publications, articles, or registry entries linked to this study.
Schwartz PJ, Zaza A. The Sicilian Gambit revisited--theory and practice. Eur Heart J. 1992 Nov;13 Suppl F:23-9. doi: 10.1093/eurheartj/13.suppl_f.23. No abstract available.
Reference Type
BACKGROUND
Zipes DP, Prystowsky EN, Heger JJ. Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. J Am Coll Cardiol. 1984 Apr;3(4):1059-71. doi: 10.1016/s0735-1097(84)80367-8.
Reference Type
BACKGROUND
Marinchak RA, Friehling TD, Kline RA, Stohler J, Kowey PR. Effect of antiarrhythmic drugs on defibrillation threshold: case report of an adverse effect of mexiletine and review of the literature. Pacing Clin Electrophysiol. 1988 Jan;11(1):7-12. doi: 10.1111/j.1540-8159.1988.tb03925.x.
Reference Type
BACKGROUND
Zhou L, Chen BP, Kluger J, Fan C, Chow MS. Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol. 1998 Jun;31(7):1672-8. doi: 10.1016/s0735-1097(98)00160-0.
Reference Type
BACKGROUND
Hohnloser SH, Dorian P, Roberts R, Gent M, Israel CW, Fain E, Champagne J, Connolly SJ. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation. 2006 Jul 11;114(2):104-9. doi: 10.1161/CIRCULATIONAHA.106.618421. Epub 2006 Jul 3.
Reference Type
BACKGROUND
Jung W, Manz M, Pizzulli L, Pfeiffer D, Luderitz B. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol. 1992 Oct 15;70(11):1023-7. doi: 10.1016/0002-9149(92)90354-2.
Reference Type
BACKGROUND
Fain ES, Lee JT, Winkle RA. Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements. Am Heart J. 1987 Jul;114(1 Pt 1):8-17. doi: 10.1016/0002-8703(87)90300-0.
Reference Type
BACKGROUND
Soar J, Berg KM, Andersen LW, Bottiger BW, Cacciola S, Callaway CW, Couper K, Cronberg T, D'Arrigo S, Deakin CD, Donnino MW, Drennan IR, Granfeldt A, Hoedemaekers CWE, Holmberg MJ, Hsu CH, Kamps M, Musiol S, Nation KJ, Neumar RW, Nicholson T, O'Neil BJ, Otto Q, de Paiva EF, Parr MJA, Reynolds JC, Sandroni C, Scholefield BR, Skrifvars MB, Wang TL, Wetsch WA, Yeung J, Morley PT, Morrison LJ, Welsford M, Hazinski MF, Nolan JP; Adult Advanced Life Support Collaborators. Adult Advanced Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Resuscitation. 2020 Nov;156:A80-A119. doi: 10.1016/j.resuscitation.2020.09.012. Epub 2020 Oct 21.
Reference Type
BACKGROUND
Sanfilippo F, Corredor C, Santonocito C, Panarello G, Arcadipane A, Ristagno G, Pellis T. Amiodarone or lidocaine for cardiac arrest: A systematic review and meta-analysis. Resuscitation. 2016 Oct;107:31-7. doi: 10.1016/j.resuscitation.2016.07.235. Epub 2016 Aug 3.
Reference Type
BACKGROUND
Tagami T, Yasunaga H, Yokota H. Antiarrhythmic drugs for out-of-hospital cardiac arrest with refractory ventricular fibrillation. Crit Care. 2017 Mar 21;21(1):59. doi: 10.1186/s13054-017-1639-8.
Reference Type
BACKGROUND
Tagami T, Matsui H, Tanaka C, Kaneko J, Kuno M, Ishinokami S, Unemoto K, Fushimi K, Yasunaga H. Amiodarone Compared with Lidocaine for Out-Of-Hospital Cardiac Arrest with Refractory Ventricular Fibrillation on Hospital Arrival: a Nationwide Database Study. Cardiovasc Drugs Ther. 2016 Oct;30(5):485-491. doi: 10.1007/s10557-016-6689-7.
Reference Type
BACKGROUND
Chowdhury A, Fernandes B, Melhuish TM, White LD. Antiarrhythmics in Cardiac Arrest: A Systematic Review and Meta-Analysis. Heart Lung Circ. 2018 Mar;27(3):280-290. doi: 10.1016/j.hlc.2017.07.004. Epub 2017 Aug 23.
Reference Type
BACKGROUND
Zhao H, Fan K, Feng G. Amiodarone and/or lidocaine for cardiac arrest: A Bayesian network meta-analysis. Am J Emerg Med. 2020 Oct;38(10):2185-2193. doi: 10.1016/j.ajem.2020.06.074. Epub 2020 Jul 5.
Reference Type
BACKGROUND
Ong ME, Pellis T, Link MS. The use of antiarrhythmic drugs for adult cardiac arrest: a systematic review. Resuscitation. 2011 Jun;82(6):665-70. doi: 10.1016/j.resuscitation.2011.02.033. Epub 2011 Mar 27.
Reference Type
BACKGROUND
Kudenchuk PJ, Leroux BG, Daya M, Rea T, Vaillancourt C, Morrison LJ, Callaway CW, Christenson J, Ornato JP, Dunford JV, Wittwer L, Weisfeldt ML, Aufderheide TP, Vilke GM, Idris AH, Stiell IG, Colella MR, Kayea T, Egan D, Desvigne-Nickens P, Gray P, Gray R, Straight R, Dorian P; Resuscitation Outcomes Consortium Investigators. Antiarrhythmic Drugs for Nonshockable-Turned-Shockable Out-of-Hospital Cardiac Arrest: The ALPS Study (Amiodarone, Lidocaine, or Placebo). Circulation. 2017 Nov 28;136(22):2119-2131. doi: 10.1161/CIRCULATIONAHA.117.028624. Epub 2017 Sep 13.
Reference Type
BACKGROUND
Kudenchuk PJ, Cobb LA, Copass MK, Cummins RO, Doherty AM, Fahrenbruch CE, Hallstrom AP, Murray WA, Olsufka M, Walsh T. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999 Sep 16;341(12):871-8. doi: 10.1056/NEJM199909163411203.
Reference Type
BACKGROUND
Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002 Mar 21;346(12):884-90. doi: 10.1056/NEJMoa013029.
Reference Type
BACKGROUND
Ristagno G, Li Y, Fumagalli F, Finzi A, Quan W. Amplitude spectrum area to guide resuscitation-a retrospective analysis during out-of-hospital cardiopulmonary resuscitation in 609 patients with ventricular fibrillation cardiac arrest. Resuscitation. 2013 Dec;84(12):1697-703. doi: 10.1016/j.resuscitation.2013.08.017. Epub 2013 Sep 1.
Reference Type
BACKGROUND
Ristagno G, Mauri T, Cesana G, Li Y, Finzi A, Fumagalli F, Rossi G, Grieco N, Migliori M, Andreassi A, Latini R, Fornari C, Pesenti A; Azienda Regionale Emergenza Urgenza Research Group. Amplitude spectrum area to guide defibrillation: a validation on 1617 patients with ventricular fibrillation. Circulation. 2015 Feb 3;131(5):478-87. doi: 10.1161/CIRCULATIONAHA.114.010989. Epub 2014 Dec 2.
Reference Type
BACKGROUND
Salcido DD, Schmicker RH, Kime N, Buick JE, Cheskes S, Grunau B, Zellner S, Zive D, Aufderheide TP, Koller AC, Herren H, Nuttall J, Sundermann ML, Menegazzi JJ; Resuscitation Outcomes Consortium Investigators. Effects of intra-resuscitation antiarrhythmic administration on rearrest occurrence and intra-resuscitation ECG characteristics in the ROC ALPS trial. Resuscitation. 2018 Aug;129:6-12. doi: 10.1016/j.resuscitation.2018.05.028. Epub 2018 May 24.
Reference Type
BACKGROUND
Frigerio L, Baldi E, Aramendi E, Chicote B, Irusta U, Contri E, Palo A, Compagnoni S, Fracchia R, Iotti G, Oltrona Visconti L, Savastano S; Lombardia CARe Researchers. End-tidal carbon dioxide (ETCO2) and ventricular fibrillation amplitude spectral area (AMSA) for shock outcome prediction in out-of-hospital cardiac arrest. Are they two sides of the same coin? Resuscitation. 2021 Mar;160:142-149. doi: 10.1016/j.resuscitation.2020.10.032. Epub 2020 Nov 10.
Reference Type
BACKGROUND
Ristagno G, Gullo A, Berlot G, Lucangelo U, Geheb E, Bisera J. Prediction of successful defibrillation in human victims of out-of-hospital cardiac arrest: a retrospective electrocardiographic analysis. Anaesth Intensive Care. 2008 Jan;36(1):46-50. doi: 10.1177/0310057X0803600108.
Reference Type
BACKGROUND
Aiello S, Perez M, Cogan C, Baetiong A, Miller SA, Radhakrishnan J, Kaufman CL, Gazmuri RJ. Real-Time Ventricular Fibrillation Amplitude-Spectral Area Analysis to Guide Timing of Shock Delivery Improves Defibrillation Efficacy During Cardiopulmonary Resuscitation in Swine. J Am Heart Assoc. 2017 Nov 4;6(11):e006749. doi: 10.1161/JAHA.117.006749.
Reference Type
BACKGROUND
Hulleman M, Salcido DD, Menegazzi JJ, Souverein PC, Tan HL, Blom MT, Koster RW. Predictive value of amplitude spectrum area of ventricular fibrillation waveform in patients with acute or previous myocardial infarction in out-of-hospital cardiac arrest. Resuscitation. 2017 Nov;120:125-131. doi: 10.1016/j.resuscitation.2017.08.219. Epub 2017 Aug 24.
Reference Type
BACKGROUND
Ruggeri L, Semeraro F, Ristagno G. Amplitude spectrum area: The "clairvoyance" during resuscitation in the era of predictive medicine. Resuscitation. 2017 Nov;120:A5-A6. doi: 10.1016/j.resuscitation.2017.09.011. Epub 2017 Sep 18. No abstract available.
Reference Type
BACKGROUND
Hulleman M, Salcido DD, Menegazzi JJ, Souverein PC, Tan HL, Blom MT, Koster RW. Ventricular fibrillation waveform characteristics in out-of-hospital cardiac arrest and cardiovascular medication use. Resuscitation. 2020 Jun;151:173-180. doi: 10.1016/j.resuscitation.2020.02.027. Epub 2020 Mar 10.
Reference Type
BACKGROUND
Aramendi E, Elola A, Alonso E, Irusta U, Daya M, Russell JK, Hubner P, Sterz F. Feasibility of the capnogram to monitor ventilation rate during cardiopulmonary resuscitation. Resuscitation. 2017 Jan;110:162-168. doi: 10.1016/j.resuscitation.2016.08.033. Epub 2016 Sep 23.
Reference Type
BACKGROUND
Freedman MD, Somberg JC. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol. 1991 Nov;31(11):1061-9. doi: 10.1002/j.1552-4604.1991.tb03673.x.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRCCSPSM 1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
In-hospital Cardiac Arrest - Dynamics and State Transitions
NCT00920244
COMPLETED
Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia
NCT00383799
TERMINATED
PHASE4
RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy
NCT00127582
UNKNOWN
PHASE3
Amantadine to Speed Awakening After Cardiac Arrest
NCT02486211
COMPLETED
PHASE2
Endocardial Pacing in On-table Non-responders in Cardiac Resynchronization Therapy
NCT01193712
WITHDRAWN
NA
AED Use in Out-of-Hospital Cardiac Arrest: A New Algorithm Named "One Shock Per Minute"
NCT00139542
COMPLETED
PHASE3
Time-dependent Amiodarone Treatment in Atrial Fibrillation
NCT03432663
COMPLETED
PHASE4
Amiodarone Usage After Ischemic Ventricular Tachycardia Ablation
NCT03244748
UNKNOWN
The Impact of Noradrenaline on Ventriculo-arterial Coupling and Central Cardiovascular Energy Delivery
NCT04745845
COMPLETED
NA
His-bundle Pacing vs. Right Ventricular Apical Pacing in Patients With Reduced Ejection Fraction
NCT04529577
RECRUITING
NA
Control Versus Liberal Cardiac Frequency in Patients in Sepse With Atrial Fibrillation of High Ventricular Response
NCT03715556
UNKNOWN
PHASE3
The Left Bundle Cardiac Resynchronization Therapy Trial
NCT05434962
ACTIVE_NOT_RECRUITING
NA
Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest
NCT03640949
COMPLETED
PHASE2/PHASE3
Effect of Closed Loop Pacemaker Treatment on Recurrent Vasovagal Syncope
NCT00292825
COMPLETED
NA
VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial
NCT05139849
RECRUITING
PHASE3
High-density Activation Mapping of the Slow Pathwayto Guide Catheter Ablation in Patients With Typical Atrioventricular Nodal Reentrant Tachycardia
NCT05531903
COMPLETED
NA
Beta-blockade With Landiolol in Out-of-hospital Cardiac Arrest
NCT05554978
UNKNOWN
PHASE1/PHASE2
Left Bundle Branch Area Pacing Using Conventional Stylet-driven Pacemaker Leads for Cardiac Resynchronization Therapy
NCT05365568
ACTIVE_NOT_RECRUITING
NA
The Leadless AV Versus DDD Pacing Study
NCT05498376
RECRUITING
PHASE4
The Relationship Between Left Atrial Pressure and Cardiac Function After Atrioventricular Node Ablation
NCT05449158
COMPLETED
NA
A Prospective Incident Study of Arrhythmias in Hypertrophic Cardiomyopathy
NCT04112290
ACTIVE_NOT_RECRUITING
Tricuspid Regurgitation Study
NCT01093001
COMPLETED
PHASE4
Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)
NCT04496518
ACTIVE_NOT_RECRUITING
Medtronic Shock-Less Study on Physician Utilization of Shock Reduction Programming
NCT00856349
COMPLETED
Vfib by ECG or Echo During Cardiac Arrest
NCT04906252
COMPLETED